We use cookies to see how investors use El Fondo and make its tools, data and markets better for you. You can accept or reject; essential cookies always stay on. Privacy Policy
Trades about 635% below its sector, cheaper than its peers on earnings.
Established in 1985 and headquartered in Taizhou, China, Wanbangde Pharmaceutical Holding Group Co., Ltd. primarily focuses on the research, development, manufacturing, and distribution of traditional Chinese medicines, active pharmaceutical ingredients (APIs), and various medicinal preparations. The company also extends its operations into the medical technology field, developing products such as orthopedic implant devices, general medical equipment, protective gear, and disposable sterile polymer medical consumables. Complementary to its product offerings, it provides specialized hospital engineering services. Initially known as Wanbangde New Building Materials Co., Ltd., the company officially adopted its current name, Wanbangde Pharmaceutical Holding Group Co., Ltd., in April 2020.
Loading the full price history…
Run your own numbersPast performance is not a forecast.
Save 002082.SZ and get told when something moves.
Get updates
A clear, direct weekly summary.
Learn the fundamentals behind this asset.
A stock is a fraction of ownership in a real company. Buy one share and you own a piece (usually a tiny piece) of every desk, factory, contract and brand the company runs. The price moves because the market keeps revising what that whole pie is worth.
The price-to-earnings ratio is how much investors are paying for one dollar of a company's profit. A multiple, never an absolute. Always compared to something: a sector, a region, the company's own past.
Dividend yield is the annual income a stock or ETF pays out, expressed as a percentage of what you paid for it. It is the visible part of total return: the cash that lands in your account every quarter, and the lever most retail investors actually feel.
Market cap is shares times price. A simple formula that produces wildly unequal numbers: a single US tech name can be worth more than every company on a LATAM exchange combined.
